Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands

Nuvation Bio Inc.

2022-Q2 EPS reported -$0.21

Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.
Cash, cash equivalents and marketable securities $806.6M as of June 30.
R&D expenses $14.0M, up from $7.3M, on higher clinical and preclinical costs.
Phase 1/2 of NUV-422 expanded to glioblastoma, breast, and prostate cancers; Phase 1 data expected 2022.
Appointed David C. Hanley as Chief Technical Operations Officer in June 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.